Cardinal Health Inc: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 3, 2023 and accepted by EDGAR at Nov 3, 2023, 08:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $54.76bn | us-gaap:Revenues |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $52.99bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $1.77bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-07-01 to 2023-09-30 | $1.20bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$14.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $14.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | −$32.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | $5.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 250,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-07-01 to 2023-09-30 | $545.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-07-01 to 2023-09-30 | $92.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2023-07-01 to 2023-09-30 | $131.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months2023-07-01 to 2023-09-30 | $500.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $3.85bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $34.69bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $43.71bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $35.06bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2023-09-30 | −$3.49bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000721371-23-000084. Last ingested by Listed: Nov 5, 2026, 12:30 ET. Listed shows no prices and gives no investment advice.